Lifeguard (LFG), an anti-apoptotic protein with high expression rates in breast cancer cells, has been identified as a molecule that inhibits death mediated by Fas. The molecular function of LFG and its regulation in the carcinogenesis of human breast and sarcoma cells, however, remains to be elucidated. In the present study, we investigated the ability of LFG expression to inhibit apoptosis induced by the alkyl-phospholipid perifosine. Results showed that LFG was able to be downregulated in selected sarcoma and breast cancer cell lines characterized by high endogenous LFG expression. A decreased LFG expression led to enhanced sensitivity to treatment with an agonistic Fas antibody or treatment with perifosine. Taken together, our findings indicate the role of LFG as an anti-apoptotic protein and provide further evidence of the potential of LFG as a target for the development of novel therapeutic strategies.
apoptosislifeguardFasperifosinecancerIntroduction
Lifeguard (LFG), a member of a unique gene family with high structural similarity (1), was isolated and identified as a molecule that inhibits death mediated by Fas in tumor cells (2). The anti-apoptotic role of LFG was confirmed in LN-18 astrocytoma, and cervical carcinoma HeLa and Jurkat T cell lines (3). However, the exact role of LFG in apoptosis remains to be determined. While it has been shown that LFG interacts with Bax and localizes in cellular membranes, including the endoplasmic reticulum and plasma membrane (4), it is well documented that endogenous LFG localizes to lipid rafts (3). Its mode of action depends on Akt/protein kinase B (PKB) signaling as dominant negative Akt/PKB inhibits LFG activity, whereas the overexpression of constitutively active Act/PKB leads to an increase in LFG activity (3). Previously, it was found that LFG expression correlates with high tumor grades in primary breast tumors and that the expression of LFG mRNA in breast cancer depends on the activity of Akt/LEF-1 signaling (5,6).
Perifosine is an alkylphospholipid (APL), a novel class of antitumor agents, structurally related to ether lipids that interact with the cell membrane, thereby modulating intracellular growth signal transduction pathways. Notably, perifosine inhibits Akt/PKB activity, which is associated with activation of the stress-activated protein kinase (SAPK)/JNK pathway, without affecting PI3-K or PDK-1 activity (7). Perifosine was found to induce apoptotic cell death in a variety of tumor cell lines and cause inhibition of PC-3 prostate carcinoma cell growth. Perifosine induces p21WAF1 expression in squamous carcinoma cells through a p53-independent pathway, leading to the loss of cyclin-dependent kinase activity and cell cycle arrest (7,8).
While it has been shown that the cellular uptake of perifosine is required in its role as an anticancer drug, the significance of lipid raft-mediated endocytosis has yet to be determined. Various studies have shown that perifosine accumulates in lipid rafts in a manner sensitive to raft disruption by cholesterol depletion (9–11). Subsequently, it was suggested that LFG, an anti-apoptotic protein with subcellular localization in lipid rafts, may interfere with perifosine-induced apoptosis. Thus, it was postulated that high expression rates of LFG confer resistance to perifosine-induced apoptosis and that downregulation of LFG expression sensitizes cell lines to this drug. Consequently, LFG expression was reduced in selected cellular models by small interfering (si)RNA transfection and the impact on perifosine-induced apoptosis was measured.
Materials and methodsCell lines and culture condition
Human breast carcinoma MCF7 and liposarcoma carcinoma SW872 cell lines were obtained from the American Type Culture Collection (Rockville, MD, USA) and grown in Dulbecco’s modified Eagle’s medium (DMEM) (PAA, Cölbe, Germany) supplemented with 10% fetal calf serum (Biochrom, Berlin, Germany) and 50 mg/ml penicillin-streptomycin. Cultures were maintained at 37°C in a humidified atmosphere with 5% CO2.
Caspase assay
Activation of caspase-3/7 was determined using the Apo-One Homogeneous Caspase-3/7 assay (Promega, Madison, WI, USA) according to the manufacturer’s instructions. Briefly, MCF-7 breast cancer and SW872 sarcoma cancer cells were seeded (1×104/well) in a 96-well plate and infected with siRNA LFG and control siRNA [107 VP (viral particles)/ml] for 48 h. After 48 h, the cells were incubated with either 25–50 ng/ml of agonistic anti-Fas (clone CH11) or 2.5–5 μM of perifosine (soluble in water at 10 mg/ml) for 4 h. Following treatment, the cells were mixed with the same volume of Apo-One Homogeneous Caspase-3/7 reagent and incubated at room temperature for 2 h. Caspase-3/7 activation was estimated from sample fluorescence at the excitation wavelength of 492 nm and the emission wavelength of 521 nm using the fluorescence plate reader Tecan GENios (Tecan Schweiz AB, Zurich, Switzerland).
Small interfering RNA
MCF-7 and SW873 cells were transfected with siRNA LFG-780 5′-gagcgggtgtatttacattg-3′ and siRNA LFG-650 5′-cctcctacccttccaatatgt-3 (designed by Sirion, Munich, Germany) and the appropriate control vector. The algorithm used by Sirion for the siRNA design was optimized for maximum gene specificity and KD efficiency. Subsequent virus rescue and production were carried out in HEK 293 cells. Virus purification was performed using the ViraBind™ Adenovirus Miniprep kit (Cell Biolabs, Inc., USA). The cells were seeded at 2×104 cells/cm2 and incubated at 37°C in a humidified atmosphere with 5% CO2 for 48 h before being analyzed.
Total RNA was extracted using the NucleoSpin RNAII kit (MN Macherey-Nagel, Duren, Germany). RNA (1 μg) was then reverse transcribed into cDNA and amplified using the iScript™ cDNA kit (Bio-Rad Laboratories, Hercules, CA, USA). The reverse (R) and forward (F) primers used were: LFG-F 5′-gactcatcctggccatcctcctac-3′ and LFG-R 5′-ggcgtcggtt acccatcagc-3′; and 18S-F 5′-gagcggtcggcgtcccccaacttc-3′ and 18S-R 5′-gcgcgtgcagccccggacatctaa-3′. PCR was carried out in 20-μl samples with 5 ng cDNA and 10 pM of each forward and reverse primer and the 2X SYBR-Green SensiMix DNA kit (Quantace, London, UK). Relative gene expression was determined by normalization of the fluorescence intensity to the expression of the 18S gene. Amplification cycles were: 40 cycles at 94°C for 30 sec, 65°C for 30 sec and 72°C for 1 min.
Results
To investigate the ability of LFG expression to suppress APL-induced apoptosis, two human solid tumor-derived cell lines with high endogenous LFG expression were selected: breast carcinoma MCF7 and liposarcoma SW872. Two siRNAs (650 and 780) were designed and tested for their silencing activity in MCF-7 and SW872 cells. Ad-sh-LFG-650 significantly decreased LFG mRNA as shown by semi-quantitative RT-PCR at 48 h following transfection (Fig. 1A).
We subsequently investigated whether downregulation of LFG expression leads to increased rates of apoptosis in the selected cell lines. The cells did not exhibit a significant increase in cellular apoptosis over a 48-h period; the level of apoptosis remained at an almost constant level comparable to the control (Fig. 1B).
Since the LFG-mediated inhibition of Fas-induced cell death is well documented in the literature, we assessed the efficiency of LFG suppression on Fas-mediated apoptosis. MCF-7 and SW872 cancer cells were infected with Ad-sh-LFG-650 and the control siRNA (107 VP/ml) vector for 48 h followed by incubation with 25–50 ng/ml of agonistic anti-Fas (clone CH11) for an additional 4 h. While a dose-dependent increase in apoptosis in the control cells indicated a general sensitivity of MCF-7 and SW872 cells to treatment with agonistic anti-Fas, we found that the cells with a downregulated expression of LFG exhhibited significantly increased rates of apoptosis (SW872: P=4.94581E-07, P=1.7476E-07; MCF7: P=2.9744E-05, P=0.00282759) indicating an increase in sensitivity to the treatment (Fig. 2A and B).
Involvement of LFG in resistance against perifosine-mediated apoptosis was assessed to test the effect of LFG downregulation in the cellular models. We transfected MCF-7 and SW872 cells with the Ad-sh-LFG-650 vector 48 h prior to perifosine treatment. Treatment of the transfected MCF-7 and SW872 cells with 2.5–5 μM perifosine for 4 h resulted in a significant increase in cell death compared to the control cells (SW872: P=0.00029973, P=0.00027001; MCF-7: P=0.04668954, P=0.00152829) (Fig. 2C and D).
To test for specificity of the observed effect, we performed rescue experiments by first transfecting SW872 cells with the Ad-sh-LFG-650 vector (downregulation) for 48 h followed by an LFG-encoding expression vector for an additional 24 h. Following the given time, cells were incubated with 50 ng/ml of agonistic anti-Fas (clone CH11) and 5 μM of perifosine. Four hours after treatment, apoptosis rates were found to be significantly decreased in the LFG-transfected cells (Fig. 3).
Discussion
In the present study, we demonstrated that silencing of LFG expression increased apoptosis in Fas- and perifosine-treated MCF7 and SW872 cancer cells (Fig. 2). This is a significant finding as clinical phase II studies on perifosine for treatment of inoperable soft tissue sarcomas (12,13) and metastatic breast cancer patients (14) are underway for the purpose of identifying sensitive tumor populations.
Although our data clearly revealed that LFG was able to reduce perifosine activity in the cell models, a number of issues require elucidation. Investigation of the cellular uptake of APL under given experimental conditions is warranted as uptake has been shown to be crucial to its antitumoral activity (10). Although different types of alkylphospholipids depend on the same modes of cellular uptake, it appears that observed differences in kinetics and efficiencies may depend on variations in the importance of singular pathways, e.g., raft-mediated endocytosis via ATP-dependent translocase activity (15,16). This may explain differences in the biological activity of modified alkylphospholipids as found in the study by Mravljak et al (17) which confirms our results of reduced sensitivity of MCF-7 cells to treatment with perifosine.
It is crucial to determine whether prolonged treatment with perifosine induces any changes in the LFG expression since perofisone is a known regulator of survival and proliferation pathways, such as PI3K/Akt and ERK 1/2 (7,18,19). Previously, we demonstrated that LFG is a new target gene of the Akt/LEF-1 pathway (6) and consequently a potential target of perifosine activity as well.
A number of studies aimed to sensitize cells to undergo apoptosis by reducing the levels of anti-apoptotic proteins, such as Bcl-2 and Bax-XL. In a large number of cell culture studies, antisense oligonucleotides have been used to block the expression of anti-apoptotic proteins, thereby sensitizing cells to chemotherapy (20–24). The results of these studies showed that altering the homeostasis of pro- and anti-apoptotic proteins can facilitate cell death, suggesting a potential therapeutic application of antisense oligonucleotides in the treatment of cancer. This is the first study to report an enhanced sensitivity to perifosine-mediated apoptosis following LFG downregulation in carcinoma cells. Collectively, these data show that LFG may serve as a target gene for developing new therapeutic strategies against certain types of cancer.
Acknowledgements
This study was funded by the Claudia-von-Schilling Breast Cancer Foundation and Niedersächsische Krebsgesellschaft. We are most grateful to AEterna Zentaris Inc. for providing perifosine. We also thank Dr Christine Radtke for the helpful discussion and critical reading of the manuscript and Nikolas Bautsch for the excellent technical assistance.
ReferencesHuLSmithTFGoldbergerGLFG: A candidate apoptosis regulatory gene familyApoptosis14125512652009SomiaNVSchmittMJVetterDELFG: an anti-apoptotic gene that provides protection from Fas-mediated cell deathProc Natl Acad Sci USA9612667126721999BeierCPWischhusenJGleichmannMFasL (CD95L/APO-1L) resistance of neurons mediated by phosphatidylinositol 3-kinase-Akt/protein kinase B-dependent expression of lifeguard/neuronal membrane protein 35J Neurosci25676567742005ReimersKChoiCYMau-ThekESequence analysis shows that Lifeguard belongs to a new evolutionarily conserved cytoprotective familyInt J Mol Med187297342006BucanVReimersKChoiCYThe anti-apoptotic protein lifeguard is expressed in breast cancer cells and tissuesCell Mol Biol Lett152963102010BucanVAdiliMYChoiCYTransactivation of lifeguard (LFG) by Akt-/LEF-1 pathway in MCF-7 and MDA-MB 231 human breast cancer cellsApoptosis158148212010KondapakaSBSinghSSDasmahapatraGPPerifosine, a novel alkylphospholipid, inhibits protein kinase B activationMol Cancer Ther2109311032003PatelVLahusenTSyTPerifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrestCancer Res62140114092002GajateCMollinedoFEdelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid raftsBlood1097117192007MollinedoFde la Iglesia-VicenteJGajateCIn vitro and in vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid raftsClin Cancer Res16204620542010Van der LuitAHVinkSRKlarenbeekJBA new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cellsMol Cancer Ther6233723452007BaileyHHMahoneyMREttingerDSPhase II study of daily oral perifosine in patients with advanced soft tissue sarcomaCancer107246224672006KnowlingMBlacksteinMTozerRA phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trialInvest New Drugs244354392006LeighlNBDentSClemonsMA Phase II study of perifosine in advanced or metastatic breast cancerBreast Cancer Res Treat10887922008Munoz-MartinezFTorresCCastanysSThe anti-tumor alkylphospholipid perifosine is internalized by an ATP-dependent translocase activity across the plasma membrane of human KB carcinoma cellsBiochim Biophys Acta17785305402008VinkSRvan der LuitAHKlarenbeekJBLipid rafts and metabolic energy differentially determine uptake of anti-cancer alkylphospholipids in lymphoma versus carcinoma cellsBiochem Pharmacol74145614652007MravljakJZeisigRPecarSSynthesis and biological evaluation of spin-labeled alkylphospholipid analogsJ Med Chem48639363992005RuiterGAZerpSFBartelinkHAnti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathwayAnticancer Drugs141671732003VinkSRvan BlitterswijkWJSchellensJHRationale and clinical application of alkylphospholipid analogues in combination with radiotherapyCancer Treat Rev331912022007DugganBJMaxwellPKellyJDThe effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinomaJ Urol166109811052001LiFSrinivasanAWangYCell-specific induction of apoptosis by microinjection of cytochrome c. Bcl-xL has activity independent of cytochrome c releaseJ Biol Chem27230299303051997StrasbergRMZangemeister-WittkeURieberMp53- independent induction of apoptosis in human melanoma cells by a bcl-2/bcl-xL bispecific antisense oligonucleotideClin Cancer Res7144614512001TortoraGCaputoRDamianoVCombined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesisClin Cancer Res7253725442001Zangemeister-WittkeULeechSHOlieRAA novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cellsClin Cancer Res6254725552000
(A) Reduction in LFG mRNA 48 h after transfection with adenoviral vector as compared to the control cells. Semi-quantitative RT-PCR was carried out in 20-μl samples with 5 ng cDNA and 10 pmol of each forward and reverse primer using the 2X SYBR-Green Sensi-Mix DNA kit. The relative gene expression was determined from the fluorescence intensity ratio of the target gene to 18S. (B) The human breast carcinoma MCF-7 and liposarcoma SW872 cell lines were transfected with Ad-sh-LFG-650 and Ad-sh-LFG-780 vectors for 48 h and analyzed for activated levels of caspase 3 using the Apo-One assay. The data are the means ± SD for triplicate determinations which were repeated in three separate experiments.
MCF-7 and SW872 cells were transfected with LFG-specific siRNA (Ad-sh-LFG-650) for 48 h. Non-transfected and Ad-sh-control vector-transfected cells were used as negative controls. Following transfection, the cells were treated with agonistic anti-Fas (clone CH11; 25–50 ng/ml) and perifosine (2.5–5 μM). Apoptosis was quantified by measuring the levels of active caspase 3 using the Apo-One assay. (A) SW872 and (B) MCF-7 cells with downregulated LFG expression showed a statistically significant increase in apoptosis compared to the control when treated with Fas (P=4.94581E-07, P=1.7476E-07 and P=2.9744E-05, P=0.00282759, respectively). Transfected (C) SW872 and (D) MCF-7 cells showed a statistically significant increase in apoptosis compared to the control when treated with perifosine (P) (P=0.00029973, P=0.00027001 and P=0.04668954, P=0.00152829, respectively). Data are the means ± SD of triplicate determinations which were repeated in three separate experiments. *p<0.05, **p<0.01, ***p<0.001 vs. the control. Checkered bar, control; white bar, Ad-sh-conrol; vertical-striated bar, LFG vector; black bar, Ad-sh-LFG-650; horizontal-striated bar, untreated control.
SW872 cells were transfected with the Ad-sh-LFG-650 vector for 48 h (downregulation). Cells were then transfected with the cDNA-LFG vector for the next 24 h (upexpression). Apoptosis was quantified by measuring the levels of active caspase 3 using the Apo-One assay. Data represent the means ± SD for triplicate determinations which were repeated in three separate experiments. *p<0.05 vs. the control. Black bar, Ad-sh-LFG-650; dotted bar, Ad-sh-LFG-650+LFG vector; white bar, Ad-sh-Ctrl.; checkered bar, control.